Aramchol™ reduces fibrosis progression in 24 weeks
Aramchol reduced liver fibrosis progression in 15 out of 16 patients and did not worsen non-alcoholic steatohepatitis in almost half of patients.
List view / Grid view
Aramchol reduced liver fibrosis progression in 15 out of 16 patients and did not worsen non-alcoholic steatohepatitis in almost half of patients.
Cypralis, has been awarded funding by Innovate UK to develop cyclophilin inhibitors targeting fibrotic diseases...